Results 231 to 240 of about 1,461,609 (326)

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. [PDF]

Front Immunol
Chen L, Zhu Y, Feng M, Zuo D, Chen G, Ji K.   +5 more
europepmc   +1 more source

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer. [PDF]

Front Immunol
Oberg HH, Deseke M, Krohn S, Winterberg D, Peipp M, Bauerschlag D, Künkele KP, Wesch D, Baumann C.   +8 more
europepmc   +1 more source

Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches. [PDF]

Front Immunol
El-Kafrawy SA, Elkafrawy MS, Azhar EI, Saeed A, Tabll AA.   +4 more
europepmc   +1 more source

Alternative Immunosuppression in Acquired Haemophilia A

Haemophilia, EarlyView.
Jayna Mistry, Gillian Lowe, Will Lester, Charles Percy   +3 more
wiley   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, Volume 157, Issue 5, Page 954-963, 1 September 2025.
What's new? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD. [PDF]

Vaccines (Basel)
Feng H, Wang Z, Li L, Li Y, Lu M, Chen X, Hu L, Sun Y, Du R, Qin R, Chen X, Jiang L, Zuo T.   +12 more
europepmc   +1 more source

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

MedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi, Izuchukwu F. Okpalanwaka, Adenike Oyegbesan, Ebenezar Okoyeocha, Mariam Oladejo, Sikiru O. Imodoye   +5 more
wiley   +1 more source

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies? [PDF]

Med Oncol
Zamani MR, Šácha P.
europepmc   +1 more source

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source